Baidu
map

Neurology:血液中神经酰胺或增加患阿尔茨海默氏症风险

2012-07-19 Beyond 生物谷

血液中较高水平的特定脂肪--神经酰胺可能增加一个人发展罹患阿尔茨海默氏症的风险,根据一项在7月18日发表于Neurology杂志上的最新研究报道。 研究报告作者梅奥诊所流行病学教授说Michelle M. Mielke博士:我们的研究确定了这种生物标志物可以作为一个潜在的治疗或预防阿尔茨海默氏症的新靶标。 在这项研究中,科研人员收集99名年龄在70和7??9之间的妇女血液测试中血清神经

血液中较高水平的特定脂肪--神经酰胺可能增加一个人发展罹患阿尔茨海默氏症的风险,根据一项在7月18日发表于Neurology杂志上的最新研究报道。

研究报告作者梅奥诊所流行病学教授说Michelle M. Mielke博士:我们的研究确定了这种生物标志物可以作为一个潜在的治疗或预防阿尔茨海默氏症的新靶标。
 
在这项研究中,科研人员收集99名年龄在70和7​​9之间的妇女血液测试中血清神经酰胺的水平,参试者被分为三组:高,中,低水平的神经酰胺三组。他们随后进行了长达9年的追访研究。研究发现在99名参加者中,那些生物标志物最高水平的妇女更容易患上阿尔茨海默氏病。中等水平生物标志物的妇女也容易患上该疾病,提高了近八倍。

Valory Pavlik博士说这些发现是重要的,因为确定准确早老年痴呆症的生物标志物可能有助于防止或延缓疾病。

未来每20年中,阿尔茨海默氏症的全球患病率将增加一倍。这无疑增加研究人员和医疗机构的负担,所以找出更有效的筛查、预防和治疗疾病策略迫在眉睫。

这项研究由国家老化研究所、国立神经疾病研究所等资助。

doi:10.1212/WNL.0b013e318264e380
PMC:
PMID:

Serum ceramides increase the risk of Alzheimer disease

Michelle M. Mielke, PhD, Veera Vankata Ratnam Bandaru, PhD, Norman J. Haughey, PhD, Jin Xia, MS, et al.

Objectives: Previous studies have shown that high serum ceramides are associated with memory impairment and hippocampal volume loss, but have not examined dementia as an outcome. The aim of this study was to examine whether serum ceramides and sphingomyelins (SM) were associated with an increased risk of all-cause dementia and Alzheimer disease (AD).

Methods: Participants included 99 women without dementia aged 70–79, with baseline serum SM and ceramides, enrolled in a longitudinal population-based study and followed for up to 6 visits over 9 years. Baseline lipids, in tertiles, were examined in relation to all-cause dementia and AD using discrete time Cox proportional survival analysis. Lipids were analyzed using electrospray ionization tandem mass spectrometry.

Results: Twenty-seven (27.3%) of the 99 women developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable AD. Higher baseline serum ceramides, but not SM, were associated with an increased risk of AD; these relationships were stronger than with all-cause dementia. Compared to the lowest tertile, the middle and highest tertiles of ceramide d18:1–C16:0 were associated with a 10-fold (95% confidence interval [CI] 1.2–85.1) and 7.6-fold increased risk of AD (95% CI 0.9–62.1), respectively. The highest tertiles of ceramide d18:1–C24:0 (hazard ratio [HR] = 5.1, 95% CI 1.1–23.6) and lactosylceramide (HR = 9.8, 95% CI 1.2–80.1) were also associated with risk of AD. Total and high-density lipoprotein cholesterol and triglycerides were not associated with dementia or AD.

Conclusions: Results from this preliminary study suggest that particular species of serum ceramides are associated with incident AD and warrant continued examination in larger studies.

拓展阅读:

JNI:大脑慢性炎症导致阿尔茨海默氏症

PNAS:β-淀粉样蛋白致阿尔茨海默氏症新机制

J Neurosci:阿尔茨海默氏症患者诊断新标志物RNA结合蛋白

Arch Gen Psychiatry:晚年抑郁症可能预示阿尔茨海默氏症

Arch Neurol:探究与阿尔茨海默氏症有关的蛋白质

Neurology:阿尔茨海默氏症者智力下降的新生物标记物

Cell:阿尔茨海默氏症研究获进展

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
    2012-10-24 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1990345, encodeId=2624199034519, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Mon Mar 25 13:11:00 CST 2013, time=2013-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999209, encodeId=2cc41999209c0, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 24 16:11:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817555, encodeId=73b2181e555fe, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Jun 07 23:11:00 CST 2013, time=2013-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816532, encodeId=8fe61816532f4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue May 21 06:11:00 CST 2013, time=2013-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469909, encodeId=3dd014699099f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510739, encodeId=a0e31510e3905, content=<a href='/topic/show?id=38ebe459755' target=_blank style='color:#2F92EE;'>#神经酰胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74597, encryptionId=38ebe459755, topicName=神经酰胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c2a10230680, createdName=xugc, createdTime=Sat Jul 21 02:11:00 CST 2012, time=2012-07-21, status=1, ipAttribution=)]
    2012-07-21 xugc

相关资讯

J App Physio:研究者揭示血液可以承载多少细胞

俗话说“血浓于水”,按字面意义来说也确实如此:与人体生命攸关的血液中约有一半是固体,其中最多的是红血球,约占40%。红血球含有红色素血红蛋白,负责运输氧气。 “令人惊异的是,红血球这一比例不仅在所有人体上基本一致,很多脊椎动物也与此相同”,耶拿大学生物与药学学院生物信息学教授Dr. Stefan Schuster介绍。因此,人们猜测,这一数值是通过进化过程保留下来的理想比例。“如果红血球低于这一

Blood:荟萃分析显示II型糖尿病患者或更易患血液肿瘤

近日,来自米利亚姆医院的研究者运用一种新的综合分析技术分析表明,II型糖尿病病人存在20%患血癌的风险,比如非霍奇金淋巴瘤、白血病和骨髓瘤。这项研究刊登在了国际著名杂志Blood上,研究数据为糖尿病和特定类型的癌症之间的联系提供了证据。 研究者Jorge Castillo表示,大多数人只认为心脏疾病、肾衰竭和糖尿病直接相关,然而在超过1900万被诊断患有糖尿病的美国人中患血癌等风险比例提高了20

Baidu
map
Baidu
map
Baidu
map